# A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

> **NCT06020833** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Roxadustat in combination with retinoic acid

## Key facts

- **NCT ID:** NCT06020833
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08
- **Primary completion:** 2025-10
- **Final completion:** 2026-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06020833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06020833, "A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06020833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*